DEF: Health In Tech Seeks Shareholder Approval for Equity Plan Expansion

Health In Tech, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, an expanded equity incentive plan, and auditor ratification.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on October 3, 2025, at 10:00 a.m. EDT.
• Key proposals include the election of five directors, amendment of the 2024 Equity Incentive Plan, and ratification of MaloneBailey, LLP as independent auditors for 2025.
• The 2024 Plan Amendment proposes to increase Class A common stock authorized for issuance from 7,677,849 shares to 10,677,849 shares.
• The amendment also proposes to include the issuance of up to 2,000,000 shares of Class B common stock, and options convertible into Class B common stock, specifically to executive officers.
• The Record Date for stockholders entitled to vote at the meeting is August 6, 2025.
• Proxy materials and the annual report will be mailed to stockholders on or about September 10, 2025.

Sentiment

Score: 6

Explanation: The filing outlines routine corporate governance matters for an annual meeting, including director elections and auditor ratification. The proposed expansion of the equity incentive plan is a positive for talent retention and motivation, but the introduction of high-vote Class B shares for executives and the potential for dilution introduce governance concerns. The overall sentiment is neutral as it's a procedural document with both standard and potentially contentious elements.

Positives

• The company is holding its annual meeting, demonstrating adherence to corporate governance practices.
• The proposed equity incentive plan expansion aims to attract, motivate, and retain key employees, directors, and consultants, which is crucial for growth.
• The appointment of independent auditors, MaloneBailey, LLP, for 2025 ensures continued financial oversight and transparency.
• A clawback policy for incentive compensation has been adopted, enhancing corporate governance and executive accountability.
• An insider trading policy is in place, prohibiting hedging and short sales by directors, officers, and significant beneficial owners, promoting fair market practices.

Negatives

• The proposed increase of 3,000,000 Class A common shares and 2,000,000 Class B common shares for the equity plan may result in additional dilution to existing stockholders.
• The introduction of Class B common stock, exclusively for executive officers, carries ten votes per share compared to one vote for Class A, potentially concentrating voting power with executive management.
• One Form 3 for Jennifer Guerrica was filed late due to administrative errors, indicating a minor compliance lapse.
• No board of directors meetings were held during 2024, as the initial public offering date was December 24, 2024.

Risks

• **Dilution Risk**: The proposed amendment to the 2024 Equity Incentive Plan will increase the total number of shares available for grant, potentially diluting the ownership percentage of current stockholders.
• **Concentration of Voting Power**: The introduction of Class B common stock, with ten votes per share and exclusively for executive officers, could further concentrate voting power in the hands of executive management, potentially reducing the influence of Class A common stockholders.
• **Executive Compensation Risk**: The discretion of the Compensation Committee in granting equity awards, combined with the increased share pool, could lead to significant executive compensation that may not always align with shareholder interests if not properly managed.
• **Legal and Regulatory Compliance**: While the company states all Section 16(a) filings were timely, one Form 3 was filed late due to administrative errors, indicating a minor risk of compliance lapses.
• **Fiduciary Duty Limitations**: Nevada law and the company's Articles of Incorporation limit the personal liability of directors for monetary damages, which may discourage stockholders from bringing lawsuits for breaches of fiduciary duties, potentially affecting investor recourse.

Future Outlook

The company intends to grant equity awards at each annual meeting for continuing directors, with prorated grants for new directors. The proposed expansion of the 2024 Equity Incentive Plan is a forward-looking strategy aimed at attracting, motivating, and retaining key employees, directors, and consultants to support future growth.

Management Comments

• Mr. Johnson has over 30 years of experience as an entrepreneur and has founded multiple successful companies in medical insurance sectors.
• Ms. Qian has over 20 years of leadership experience in global financial services, capital markets and fortune 100 companies.
• Mr. Lockett coordinates with Mr. Johnson to enhance sales, expand the company's capabilities, and strengthen support systems.
• Mr. Yousuf is a distinguished engineering executive, with over 10 years of strategic leadership experience.
• Mr. Plantholt has over 20 years of experience in insurance, emerging technology, and media, focusing on business growth, innovation, and strategic leadership.
• Ms. Babcock's areas of responsibility include staffing, account executive, and human resources.
• The Board of Directors recommends a vote FOR the election of each of the nominees for director (Proposal One); FOR the 2024 Plan Amendment Proposal (Proposal Two); and FOR the ratification of MaloneBailey, LLP as our independent auditors for the year ending December 31, 2025 (Proposal Three).

Industry Context

This filing is a standard proxy statement for an annual meeting, common across publicly traded companies. The proposed expansion of the equity incentive plan, particularly with the introduction of Class B common stock with enhanced voting rights for executive officers, is a notable corporate governance trend seen in some technology and growth-oriented companies. This structure is often aimed at maintaining founder/insider control and long-term strategic vision. The company operates in the 'Health In Tech' sector, suggesting a focus on technology within the healthcare or insurance industry, where attracting and retaining skilled talent through equity incentives is crucial for competitive advantage.

Comparison to Industry Standards

• The dual-class share structure (Class A with one vote, Class B with ten votes) for executive officers is a governance model adopted by some tech giants (e.g., Google/Alphabet, Meta/Facebook) to allow founders/executives to retain control and pursue long-term strategies without immediate pressure from public markets. However, it is often criticized by corporate governance advocates for disenfranchising common shareholders.
• The proposed equity pool increase of 5,000,000 shares (3M Class A + 2M Class B) for a company with 56,389,291 total shares outstanding (44,689,291 Class A + 11,700,000 Class B as of the Record Date) represents a significant potential dilution of approximately 8.8% (5M / 56.38M). This is on the higher side compared to typical annual equity grants in mature companies but might be considered within range for growth-stage tech companies.
• The audit fees of $611,717 for 2024 are within a reasonable range for a public company of its likely size, especially considering its recent IPO in December 2024, which often involves higher initial audit costs.

Management Changes

Corporate Governance

Legal Proceedings

• To the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item 401(f) of Regulation S-K in the past ten years.

Related Party Transactions

• In 2023, the company received $18,242 from a related party, which was an advanced expense payment made for the related party in 2022. The amount due from the related party was $0 as of December 31, 2024 and 2023.
• Roscommon and Roscommon Captive Management LLC, a self-insurance carrier business previously owned by CEO Tim Johnson, provided approximately $940,915 in services fees to the company's clients through May 31, 2023, before being sold to an unrelated party.

Stakeholder Impact

• **Shareholders**: Face potential dilution from the expanded equity incentive plan. Class A shareholders may experience reduced voting power relative to executive officers due to the introduction of Class B common stock with 10 votes per share. They have the opportunity to vote on key corporate governance matters.
• **Executive Officers**: Stand to significantly benefit from the expanded equity incentive plan, including exclusive eligibility for Class B common stock with enhanced voting rights, and substantial compensation packages.
• **Employees and Consultants**: Will benefit from the expanded equity incentive plan, which aims to attract, motivate, and retain them through various equity awards.
• **Directors**: Receive compensation including cash and equity awards, and are provided protection through indemnification agreements.
• **Auditors**: MaloneBailey, LLP's appointment as independent auditors is up for ratification, ensuring their continued engagement for the 2025 fiscal year.

Next Steps

• Stockholders are to vote on proposals at the 2025 Annual Meeting on October 3, 2025.
• Elect five persons to the Board of Directors.
• Approve the amendment to the Health in Tech Equity Incentive Plan (2024).
• Ratify the appointment of MaloneBailey, LLP as independent auditors for 2025.
• The Corporate Secretary is to receive stockholder proposals for the 2026 annual meeting by May 13, 2026 (pursuant to Rule 14a-8).
• Notice for soliciting proxies in support of director nominees for the 2026 annual meeting must be received by August 4, 2026 (pursuant to Rule 14a-19).

Key Dates

Recommendation

The filing primarily addresses routine annual meeting proposals and corporate governance updates. While the expansion of the equity incentive plan is a positive for talent retention, the significant potential dilution and the introduction of high-vote Class B shares for executives raise governance concerns that could be viewed negatively by some investors. There are no immediate financial performance updates or major strategic shifts that would warrant a strong buy or sell recommendation. The company's recent IPO suggests it is in an early public growth phase, and this filing is more about structural governance than operational performance. Investors should hold and monitor future financial results and the actual impact of the equity plan.

Keywords

Health In Tech, Proxy Statement, Annual Meeting, Stockholder Vote, Equity Incentive Plan, Class A Common Stock, Class B Common Stock, Director Election, Corporate Governance, Executive Compensation, MaloneBailey LLP, Auditor Ratification, Stock Dilution, Voting Rights, SEC Filing